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Abstract 
The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. 
There are limited data on the prevalence of the metabolic syndrome in European patients suffering from 
schizophrenia. 
Methods: All consecutive patients with schizophrenia at our university psychiatric hospital and affiliate services 
were entered in an extensive prospective metabolic study including an oral glucose tolerance test. The prevalence 
of the metabolic syndrome was assessed based on the National Cholesterol Education Program criteria (NCEP, 
Adult Treatment Protocol, ATP-III), adapted ATP-III criteria using a fasting glucose threshold of 100 mg/dl 
(AHA) and on the recently proposed criteria from the International Diabetes Federation (IDF). 
Results: The analysis of 430 patients showed a prevalence of the metabolic syndrome of 28.4% (ATP-III), 32.3% 
(ATP-III A) and 36%) (IDF), respectively. The prevalence of the metabolic syndrome in our sample of patients 
with schizophrenia is at least twice as high compared to an age-adjusted community sample in Belgium. 
Conclusion: The metabolic syndrome is highly prevalent among treated patients with schizophrenia. It represents 
an important risk for cardiovascular and metabolic disorders. Assessment of the presence and monitoring of the 
associated risks of the metabolic syndrome should be part of the clinical management of patients treated with 
antipsychotics. 
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1. INTRODUCTION 
Metabolic abnormalities have consistently been identified as a part of schizophrenic illness (Allison et al., 1999; 
Homel et al., 2002; Meduna et al., 1942; Raphael, 1921). The interest in this topic has recently been renewed 
since the introduction of second generation antipsychotics and their possible association with metabolic 
abnormalities (Allison and Casey, 2001; Jin et al., 2004; Meyer and Koro, 2004). The issue of abnormalities in 
glucose metabolism, in particular diabetes mellitus (DM), has hereby received most attention (De Nayer et al., 
2005; Haupt and Newcomer, 2001; Jin et al., 2002, 2004; Newcomer, 2005; Scheen and De Hert, 2005). 
However, other conditions such as cardiovascular morbidity, abnormal lipid metabolism and obesity also have a 
serious impact on the physical health of patients diagnosed with schizophrenia. The importance of diagnosing 
and treating these medical conditions needs to be stressed. Not only is the presence of these conditions 
associated with a excess mortality rate because of elevated cardiovascular risk (Brown, 1997; Brown et al., 2000; 
Osby et al, 2000a,b), it has also been associated with a lower functional outcome (Lyketsos et al, 2002), a higher 
prevalence of psychotic and depressive symptoms (Dixon et al., 1999), a worse perceived physical health (Dixon 
et al., 1999; Meyer et al, 2005) and lower adherence to medication (Robinson et al., 2002; Weiden et al, 2004). 
Therefore, researchers have developed a growing interest in the Metabolic Syndrome (MetS), which comprises 
abnormalities in glucose metabolism, lipid metabolism, obesity and blood pressure. The most commonly used 
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definitions for the Metabolic Syndrome are the Adult Treatment Protocol (ATP-III) of the National Cholesterol 
Education Program (NCEP) (Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol 
in Adults, 2001), and the adapted ATP-III A proposed by the AHA following the ADA lowering of the threshold 
for impaired fasting glucose to 100 mg/dl (Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus, 2003; Grundy et al., 2004). A more recent definition, by the International Diabetes Federation (IDF, 
2005), stressed the importance of waist circumference, using both more stringent and ethnic-/race-specific 
criteria. Recent research on MetS in the general population has indeed provided evidence for the development of 
ethnic-/race-specific criteria (Cossrow and Falkner, 2004; Ford et al., 2002; Park et al., 2003; Kraja et al., 2005; 
Misra et al, 2005; Rakugi and Ogihara, 2005). Until now, it has remained unclear to what extent these 
differences in the general population are due to genetic factors or cultural factors such as life style or economic 
factors. 
To evaluate the prevalence of MetS in patients diagnosed with schizophrenia and the impact of life style and 
economic factors within distinct ethnic groups, prospective large sample studies in different countries are 
needed. Only few studies on the prevalence of MetS among patients diagnosed with schizophrenia are available. 
The prevalence of MetS in these studies was around 40% (Basu et al., 2004; Heiskanen et al, 2003), but limited 
conclusions can be drawn from these studies because of their limited sample sizes. A large study by Cohn et al. 
of 240 Canadian subjects revealed a prevalence rate of 42.6% for males and 48.5% for females (Cohn et al., 
2004). These figures are comparable to those found in the CATIE study by McEvoy et al. who found prevalence 
rates of 36.6% for males and 54.2% for females (McEvoy et al., 2005). To our knowledge, this is the first large 
sample European study on the prevalence of MetS. In a preliminary report, a prevalence rate of 22% among a 
sample of 100 patients was found (De Hert et al., in press). We therefore hypothesized that the prevalence rate of 
MetS for our sample of 430 schizophrenic subjects would be lower than the US and Canadian prevalence rates 
found by McEvoy et al. and Cohn et al., respectively. 
2. METHODS 
All consecutive patients with a DSM-IV diagnosis of schizophrenia or schizoaffective disorders (18.6%), both 
out- (28.4%) or in-patients, of a university psychiatric hospital and affiliate services, were asked to participate in 
an extensive screening and prospective follow-up study of metabolic parameters. The prospective inclusions 
started in November 2003. At baseline, patients received a full-fasting laboratory screening, clinical 
measurements and an ECG. A 75-g glucose load Oral Glucose Tolerance Test (OGTT) was performed in a large 
subsample of patients. Patients were initiated on an overnight fast and were monitored during the OGTT. All 
laboratory analyses were performed in the same laboratory. 
Table 1-Definitions of the metabolic syndrome 
Criteria ATP-IIIa ATP-III Aa IDFb
M>102, M>102, M≥94, Waist (cm) 
F>88 F>88 F≥80 
Obligatory 
criterion 
BPC ≥130/85 ≥130/85 ≥ 130/85 






TG (≥ 150 mg/dl) ≥150 ≥150 ≥150 
Glucose (mg/dl)d ≥110 ≥100 ≥100 
a MetS if 3 of 5 criteria are met. 
b MetS if additional 2 criteria are met (waist is obligatory). 
d Or if treated with antihypertensive medication. Or if treated with insulin or hypoglycaemic medication. 
 
The presence of the MetS was assessed using the ATP-III criteria, the adapted ATP-III criteria (AHA; fasting 
glucose ≥ 100 mg/dl) and the recent IDF criteria. For the diagnosis of diabetes and pre diabetic abnormalities, we 
used the criteria of The American Diabetes Association [impaired fasting glucose (IFG) ≥ 100 mg/dl and 
impaired glucose tolerance (IGT), glucose >140 mg/dl at 2 h in the OGTT] (Expert Committee, 1997, 2003). 
Descriptive statistics were computed for the basic demographic and clinical variables as well as for the variables 
relevant for the evaluation of metabolic abnormalities. The influence of the presence/absence of the metabolic 
syndrome and the presence/absence of glucose abnormalities on continuous variables was assessed by means of 
an independent samples t-test. The association between categorical variables was evaluated by a Chi-square test 
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(Table 1). 
The study was approved by an ethical committee and all patients gave written informed consent. 
3. RESULTS 
The mean age of the patients was 36.5 years (S.D. =11.8) and the mean duration of illness was 13.0 years (S.D. = 
l0.l). 64.9% of the patients were male. 99% were white and Belgian natives. For 404 of 418 patients in our 
sample (excluding patients being treated for diabetes, n = 12), an OGTT could be done at baseline. No 
significant differences in age or sex were found between the patients that were tested and that were not tested. 
All patients were treated with antipsychotic medication. On average they received 3.2 (S.D. = 2.0) different 
medications. Antipsychotics were combined with anticholinergics (15.8%), antidepressants (38.6%), 
benzodiazepines (33.7%), mood stabilisers (24.6%) and somatic medication (43.2%). 2.3% (12 patients) was 
being treated for diabetes, 1.9% of patients took a statin (8 patients) and 10.5% (45 patients) took 
antihypertensive medication. 
The majority of patients were treated with only one antipsychotic (87%). 77.2% of this group received a second-
generation antipsychotic, 9.8% a first-generation antipsychotic. The remaining patients took a combination of 2 
antipsychotics. 8.1% combined a first- with a second-generation agent, 4.4% combined 2 second-generation 
drugs and 0.5% combined first-generation antipsychotics. The overall distribution of antipsychotics was: 16.7% 
first-generation antipsychotics; 6.6% amisulpride; 0.2% aripiprazole; 16.1% clozapine, 30.3% olanzapine, 11.7% 
quetiapine and 18.5% risperidone. 
Table 2-Metabolic syndrome and criteria prevalence among all subjects 
Criteria All Male (N=279) Female (N=151) 
MS ATP-III 28.4% (122) 28.0% (78) 29.1% (44) 
  Waist (M> 102, F>88) 37.4% (161) 28.0% (78) 55.0% (83) 
  BP (≥ 130/85) 48.8% (210) 49.8% (139) 47.0% (71) 
  HDL (M<40 mg/dl, F < 50 mg/dl) 29.8% (128) 30.8% (86) 27.8% (42) 
  TG(≥ 150 mg/dl) 42.3% (182) 45.5% (127) 36.4% (55) 
  Glucose (≥ 110 mg/dl) 10.9% (47) 9.7% (27) 13.2% (20) 
MS ATP-III A (AHA) 32.3% (139) 30.5% (85) 35.8% (54) 
  Waist (M> 102, F>88) 37.4% (161) 28.0% (78) 55.0% (83) 
  BP (≥ 130/85) 48.8% (210) 49.8% (139) 47.0% (71) 
  HDL (M<40 mg/dl, F < 50 mg/dl) 29.8% (128) 30.8% (86) 27.8% (42) 
  TG(≥ 150 mg/dl) 42.3% (182) 45.5% (127) 36.4% (55) 
  Glucose (≥ 100 mg/dl) 25.3% (109) 22.6% (63) 30.5% (46) 
MS IDF 36.0% (155) 34.1% (95) 39.7% (60) 
  Waist (M≥94, F≥80) 62.1% (267) 55.5% (155) 74.2% (112) 
  BP (≥ 130/85) 48.8% (210) 49.8% (139) 47.0% (71) 
  HDL (M<40 mg/dl, F < 50 mg/dl) 29.8% (128) 30.8% (86) 27.8% (42) 
  TG(≥ 150 mg/dl) 42.3% (182) 45.5% (127) 36.4% (55) 
  Glucose (≥ 100 mg/dl) 25.3% (109) 22.6% (63) 30.5% (46) 
 
The prevalence rates of the MetS according to the different definitions in our sample were 28.4% (ATP-III), 
32.3% (ATP-III A), and 36% (IDF). The presence of the specific criteria and the number of criteria are shown in 
Tables 2 and 3. 
The MetS was more prevalent in female patients. This difference was mainly explained by more frequent central 
obesity. Significantly more female patients were obese (29.1% obese, 22.5% overweight) compared to male 
patients (14.0% obese, 42.3% overweight) (χ2 = 22.97, p<.0001). Female patients were significantly more likely 
to meet the increased waist criterion according either to ATP-III and ATP-III A (χ2 = 30.51, p<.0001) or IDF 
MetS (χ2= 14.43,p<.000l). 
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There was a highly significant effect of age on the prevalence of MetS, regardless of the definition used 
(p<.0001, t-test, respectively, 14.85, 22.01, 30.09). Patients with the MetS were, on average, 5 years older than 
patients without the MetS. There was no significant difference in the prevalence of MetS between antipsychotic 
agents in this cross-sectional analysis. 
Table 3-Metabolic syndrome and number of criteria prevalence among all subjects 
 All (N=430) Male (N=279) Female (N=151) 
Men age (years) 36.5 ± 11.8 34.7 ± 11.3 39.9 ± 11.6 
Mean BMI (kg/m2) 26.0 ± 5.0 25.7 ± 4.3 26.6 ± 6.1 
 
Criteria met:    
MS ATP-III 28.4% (122) 28.0% (78) 29.1% (44) 
0 24.2% 25.8% 21.2% 
1 26.7% 27.2% 25.8% 
2 20.7% 19.0% 23.8% 
3 15.1% 15.0% 15.2% 
4 10.4% 11.1% 9.3% 
5 2.8% 1.8% 4.6% 
MS ATP-III A (AHA) 32.3% (139) 30.5% (85) 35.8% (54) 
0 21.9% 23.3% 19.2% 
1 24.9% 25.4% 23.8% 
2 20.9% 20.8% 21.2% 
3 16.3% 15.4% 17.9% 
4 12.1% 11.8% 12.6% 
5 3.9% 3.2% 5.3% 
MS IDF 36.0% (155) 34.1% (95) 39.7% (60) 
Waist Additional criteria 62.1% (267) 55.5% (155) 74.2% (112) 
0 24.9% 44.3% 26.5% 
1 30.2% 55.6% 30.5% 
2 24.2% 45.0% 23.8% 
3 15.1% 29.8% 13.2% 
4 5.6% 9.9% 6.0% 
 
Table 4-Relationship between the metabolic syndrome and glucose abnormalities 
 Normal values Pre diabetes Diabetes Total 
ATP-III 
No 54.2% (233) 16.1% (69) 1.4% (6) 71.6% (308) 
Yes 12.3% (53) 8.8% (38) 7.2% (31) 28.4% (122) 
ATP-III A 
No 54.2% (233) 12.3% (53) 1.2% (5) 67.7% (291) 
Yes 12.3% (53) 12.6% (54) 7.4% (32) 32.3% (139) 
IDF 
No 51.2% (220) 11.4% (49) 1.4% (6) 64.0% (275) 
Yes 15.4% (66) 13.5% (58) 7.2% (31) 36.0% (155) 
Total 66.5% (286) 24.9% (107) 8.6% (37)  
 
According to ADA criteria 8.6% of patients met criteria for diabetes, another 24.9% met criteria for prediabetes 
(20% IFG, 13.3% IGT, either isolated or in combination). The prevalence of the metabolic syndrome was 
significantly higher in diabetic subjects (ATP-III 83.78%, ATP-III A 86.5%, IDF 83.78%) compared to patients 
with pre diabetic abnormalities (ATP-III 35.1%, ATP-III A 50.47%, IDF 54.21%) and patients without glucose 
abnormalities (ATP-III 18.53%, ATP-III A 18.53%, IDF 23.08%). Patients with MetS were more likely to meet 
criteria for diabetes or pre diabetic abnormalities in all definitions of the MetS applied (df=2, respectively, χ2 = 
75.22, 90.59 and 72.75,p<.0001) (Table 4). 
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All parameters evaluated in the OGTT (glucose and insulin values fasting, at 30 min, at 60 min and 120 min) as 
well as HOMA-IR and glycosylated haemoglobin Alc were significantly different between patients with or 
without the metabolic syndrome regardless of the definition (p<.0001). All values are higher in patients with 
MetS. Similar highly significant differences were found on all fasting serum lipid values and calculated lipid risk 
factors for cardiovascular disease (cholesterol, triglycerides, HDL, LDL, NON-HDL cholesterol, CHOL/HDL 
and LDL/HDL) (p<.0001). 
4. DISCUSSION 
Our study on the prevalence of MetS in patients diagnosed with schizophrenia is the largest study on a European 
schizophrenic population as of today. It confirms the high prevalence of MetS in this population, reaching as 
much as twice the prevalence of the general Belgian population (Rietzschel et al., 2005). The age-adjusted MetS 
prevalence was 12% in this community sample and MetS was almost twice as prevalent in male compared to 
female subjects (16% vs. 9%). Furthermore, the presence of the MetS was associated with an elevated presence 
of diabetes and cardiovascular risk factors. The prevalence of diabetes in this population is 3 times higher than in 
the general population. Therefore, these data clearly demonstrate the need for screening for MetS in patients 
diagnosed with schizophrenia, as suggested by De Nayer et al. (2005) and Marder et al. (2004). 
As hypothesized, there was a considerable difference in prevalence rates between our study and the CATIE 
study. Because our sample consisted of mainly white subjects (99%), a comparison is best made with the white 
subject subsample of the CATIE cohort. Hence, the difference remains considerable. Prevalence rates in our 
sample using ATP-IIIA criteria were 30.5% for male patients and 35.8% for female patients, compared to 44.4% 
for white male patients and 58.1% for white female patients in the CATIE study. The explanation for the 
difference in prevalence rates could well be life style differences in the European vs. the American population. 
Unfortunately, to our knowledge, no study has specifically handled this issue. Moreover, an important 
geographical variation of the prevalence rate of MetS within the US population was reported (Ford et al., 2005), 
further complicating the interpretation of the difference in prevalence rates, especially since our recruitment of 
patients was restricted to one site. Nevertheless, estimates in the general population have consistently been lower 
for European than for US populations (Boulogne and Vantyghem, 2004; Ferreira et al., 2005; Ford et al., 2002, 
2004; Hu et al, 2004). These findings clearly show the necessity of a careful demographic and symptomatic 
description and prospective follow-up of different cohorts in distinct areas, in order to determine the influence of 
life style and genetics to the diagnosis and treatment of MetS. 
The current study also has some limitations. First, it is a cross-sectional study. We intent to follow-up this cohort 
prospectively, in order to assess metabolic changes  during  the  course  of the  illness  and in function of 
antipsychotic regimes. Second, patient recruitment was restricted to one site, which could have influenced our 
results, as described above. Third, we failed to include other parameters, such as dietary habits, physical activity 
level, and schizophrenic and affective symptoms. Future research should address these issues more specifically, 
in large, multi-site samples and with prospective study designs. 
In conclusion, our data confirm the high prevalence of MetS for a European population of patients. Caregivers 
should carefully monitor and treat metabolic abnormalities in patients diagnosed with schizophrenia. 
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